Clinical Trials
17 trialsNCT04527991 2026-06-02
TROPiCS-04
Gilead Sciences
Phase 3 Completed
NCT07419295 2026-05-29
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03390504 2026-05-11
THOR
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03474107 2026-01-09
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Phase 3 Completed
NCT00545766 2021-12-16
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02256436 2021-09-20
MK-3475-045
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02057913 2020-07-23
VinCaP
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT02302807 2019-08-01
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche
Phase 3 Completed
NCT01844947 2019-04-26
VINSOR
Karolinska University Hospital
Phase 1 Completed
NCT01529411 2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02845050 2018-02-13
JaNEO
Ligartis GmbH
Phase 1/2 Withdrawn
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT01265940 2012-10-10
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Lukas-Krankenhaus GmbH
Phase 1/2 Completed
NCT00101608 2010-03-02
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Bristol-Myers Squibb
Phase 2 Completed
NCT00315237 2010-01-07
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
Bristol-Myers Squibb
Phase 3 Completed